Our data indicating that Net1 deletion switched tumors to a wild-type p53 gene expression signature (Fig. 6c) may also suggest that targeting Net1 would sensitize breast tumors with wild-type p53 to chemotherapies dependent on p53 function. The gene discussed is TP53; the disease is breast neoplasm.